Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Sees Significant Decrease in Short Interest

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totalling 105,900 shares, a drop of 17.1% from the August 15th total of 127,800 shares. Approximately 2.6% of the shares of the stock are sold short. Based on an average trading volume of 369,400 shares, the short-interest ratio is currently 0.3 days.

Hedge Funds Weigh In On Freeline Therapeutics

A number of institutional investors have recently bought and sold shares of FRLN. Acadian Asset Management LLC acquired a new position in shares of Freeline Therapeutics in the first quarter worth about $30,000. Thrivent Financial for Lutherans acquired a new position in Freeline Therapeutics in the 4th quarter worth approximately $37,000. Northern Trust Corp purchased a new position in Freeline Therapeutics during the 2nd quarter worth approximately $40,000. Federated Hermes Inc. grew its position in Freeline Therapeutics by 50.0% during the 1st quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $67,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Freeline Therapeutics by 17.4% during the 1st quarter. Renaissance Technologies LLC now owns 230,600 shares of the company’s stock valued at $105,000 after purchasing an additional 34,210 shares during the period. Hedge funds and other institutional investors own 46.26% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on FRLN. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Freeline Therapeutics in a report on Thursday, August 17th. Stifel Nicolaus boosted their price objective on Freeline Therapeutics from $1.00 to $3.00 in a research note on Wednesday, May 31st. 500.com reaffirmed a “reiterates” rating on shares of Freeline Therapeutics in a research note on Wednesday, May 31st. Finally, Wedbush reaffirmed an “outperform” rating and set a $5.00 target price on shares of Freeline Therapeutics in a report on Tuesday, August 15th.

Freeline Therapeutics Trading Down 3.6 %

Freeline Therapeutics stock traded down $0.15 during mid-day trading on Tuesday, hitting $4.03. The company’s stock had a trading volume of 2,640 shares, compared to its average volume of 172,273. Freeline Therapeutics has a twelve month low of $2.11 and a twelve month high of $12.60. The stock’s fifty day moving average price is $4.05 and its two-hundred day moving average price is $4.36.

Freeline Therapeutics (NASDAQ:FRLN) last issued its earnings results on Tuesday, August 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.62) by $3.41. The company had revenue of $0.62 million during the quarter. On average, research analysts predict that Freeline Therapeutics will post -1.04 EPS for the current fiscal year.

About Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease.